IP Library Granted Patent US 7,390,906
Granted Patent B2
US 7,390,906 · App. 11/455,531 · Granted Jun 24, 2008

Piperidine derivatives and process for their production

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,390,906
App. No.
11/455,531
Granted
Jun 24, 2008
Kind
B2
Abstract

The present invention relates to substantially pure piperidine derivative compounds of the formulae: wherein R 1 is hydrogen or hydroxy; R 2 is hydrogen; or R 1 and R 2 taken together form a second bond between the carbon atoms bearing R 1 and R 2 ; R 3 is —COOH or —COOR 4 ; R 4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.

Claims (39)

1. A process of preparing a piperidine derivative compound of the formula:

wherein

R 1 is hydrogen or hydroxy;

R 2 is hydrogen;

or R 1 and R 2 taken together form a second bond between the carbon atoms bearing R 1 and R 2 ;

R 3 is —COOH or —COOR 4 ;

R 4 has 1 to 6 carbon atoms;

said process comprising:

providing a regioisomer of the following formula:

converting the regioisomer to the piperidine derivative compound with a piperidine compound of the formula:

2. A process according to claim 1 , wherein said providing comprises:

acylating a starting compound of the formula:

wherein

R 5 is OR 6 , —N(R 6 ) 2 , and —SR 6 , and

R 6 is an alkyl with 1 to 6 carbons, with a compound of the formula:

wherein

X is a halogen, under conditions effective to produce a first mixture of regioisomers of the formula:

hydrolyzing the first mixture of regioisomers under conditions effective to form a second mixture of a regioisomers of the formula:

recovering from the second mixture of regioisomers the regioisomer of the formula:

3. A process according to claim 2 , wherein said recovering comprises:

crystallizing from the second mixture of regioisomers a regioisomer salt of the formula:

wherein X + is a Lewis Acid;

isolating the regioisomer salt; and

converting the regioisomer salt to the regioisomer of the formula:

4. A process according to claim 3 , wherein X + is an alkali metal salt or an ammonium salt of the form NR 7 R 8 R 9 wherein R 7 , R 8 , and R 9 are individually hydrogen or a straight or branched alkyl of 1 to 6 carbon atoms, or an alkyl substituted at any position with a phenyl ring or a substituted phenyl ring.

5. A process according to claim 2 , wherein said acylating is carried out by a Friedel-Crafts reaction using AlCl 3 catalyst.

6. A process according to claim 1 , further comprising:

reducing the piperidine derivative under conditions effective to form a hydroxylated piperidine derivative of the formula:

7. A process according to claim 6 , wherein the hydroxylated piperidine derivative has the formula:

8. A process according to claim 1 , wherein said converting comprises:

halogenating the regioisomer of the following formula:

under conditions effective to form a first intermediate compound of the formula:

wherein X is a halogen and

reacting the first intermediate compound with a piperidine compound of the formula:

under conditions effective to form the piperidine derivative of the following formula:

9. A process according to claim 1 , wherein said converting comprises:

reacting the regioisomer of the following formula:

with a piperidine compound of the formula:

under conditions effective to form the piperidine derivative of the formula:

Assignments (10)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 7541537 PREVIOUSLY RECORDED AT REEL: 034045 FRAME: 0951. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Aug 14, 2018
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 046796/0352 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2017
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC; AMRI SSCI, LLC; EUTICALS INC.
Reel/Frame 043742/0085 →
SECURITY INTEREST Recorded Oct 24, 2014
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 034045/0951 →
RELEASE OF SECURITY INTEREST Recorded Jul 9, 2014
From: WELLS FARGO
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 033283/0357 →
SECURITY AGREEMENT Recorded Apr 20, 2012
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI RENESSELAER, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 028078/0227 →
TERMINATION Recorded Apr 19, 2012
From: BANK OF AMERICA, N.A.
To: ALBANY MOLECULAR RESEARCH, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI BURLINGTON, INC.; AMRI RENESSELAER, INC.
Reel/Frame 028072/0335 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 6, 2011
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI RENSSELAER, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI BURLINGTON, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026397/0001 →
MERGER Recorded Feb 8, 2010
From: AMR TECHNOLOGY, INC.
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 023905/0317 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2009
From: AMR TECHNOLOGY, INC.
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 022092/0512 →
LICENSE Recorded Dec 12, 2006
From: AMR TECHNOLOGY, INC. (F.K.A. ALBANY MOLECULAR RESEARCH INC.)
To: AVENTIS PHARMACEUTICALS INC. (F.K.A. MARION MERRELL DOW INC.)
Reel/Frame 018616/0373 →